Haisco Pharmaceutical Group 海思科
48 significant filings since 30 May 2026: 1 on share pledge, 22 on share issue and 10 on equity incentive, and 10 other kinds. The latest, on 18 Sep 2026: 关于2024年限制性股票激励计划第二个解除限售期解除限售条件成就的公告. On 9 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 513.25% to 575.35% from the same period a year earlier.
自 30 May 2026 起有 48 份重大公告：share pledge 1 份、share issue 22 份、equity incentive 10 份，另有 10 类。最新一份（18 Sep 2026）：关于2024年限制性股票激励计划第二个解除限售期解除限售条件成就的公告。9 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 513.25% 至 575.35%。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 16 Sep 2026 | 山西证券 | 邓周宇,魏赟,张智勇 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 山西证券 | 邓周宇,魏赟,张智勇 | Buy 买入 | 16 Sep 2026 | 1 | 82.09 |
| 西南证券 | 杜向阳 | Unrated | 10 Sep 2026 | 1 | — |
| 太平洋 | 谭紫媚,张懿 | Buy 买入 | 4 Sep 2026 | 2 | — |
| 东吴证券 | 朱国广 | Buy 买入 | 30 Aug 2026 | 1 | — |
| 国信证券 | 马千里,陈曦炳,彭思宇 | Outperform 增持 | 21 Apr 2026 | 1 | — |
| 开源证券 | 余汝意,刘艺 | Buy 买入 | 14 Apr 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 2 of 7 reports. 每行为该券商近十二个月的最新研报；7 份中 2 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。